Business Context and Reporting Period
Company: Vital Therapies, Inc. (Note: Request metadata referenced "IMMUNIC, INC.", but the filing text identifies the registrant as Vital Therapies, Inc.)
Filing Type: Form 8-K (Current Report)
Date: May 1, 2014
Context: The filing reports a significant clinical milestone for the company's lead product candidate, VTI-208.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on a clinical trial milestone and does not contain financial statements.
Material Changes
- Clinical Milestone: On May 1, 2014, the company announced the enrollment of the 100th subject in its Phase 3 randomized, controlled clinical trial of VTI-208.
- Trial Scope: The trial targets 200 subjects total with alcohol-induced liver decompensation (AILD).
Guidance, Outlook, and Risks
Management Commentary: The filing references a press release (Exhibit 99.1) detailing the clinical progress but does not include forward-looking financial guidance or specific risk factors within the text of the 8-K itself.
Unusual Items: None reported in this specific filing.
Investor Verification Checklist
- Verify the full text of the press release (Exhibit 99.1) for details on the VTI-208 Phase 3 trial design and timeline.
- Confirm the total enrollment status of the 200-subject trial and any subsequent updates regarding the remaining 100 subjects.
- Review the company's most recent 10-Q or 10-K for current cash runway and burn rate, as this 8-K contains no financial data.
- Monitor regulatory communications regarding the AILD indication for VTI-208.